Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Oscient Pharmaceuticals's commercialization partner for Factive tablets, Menarini Group, has submitted a regulatory filing seeking approval of Factive in Europe.
Subscribe to our email newsletter
Menarini is seeking approval of Factive for the treatment of community-acquired pneumonia, acute bacterial exacerbations of chronic bronchitis and acute bacterial sinusitis. The regulatory review time in Europe is approximately 12 months.
Steven Rauscher, president and CEO of Oscient, said: “Menarini’s pursuit of marketing approval for Factive in Europe is an important step in our commercialization plan for Factive in our licensed territories. Menarini is a strong, experienced partner, and we look forward to working together to build the Factive brand in Europe.”